|
| Wednesday, 1 June 2016, 14:19 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, June 1, 2016 - (JCN Newswire) - AbbVie GK (Headquarters: Tokyo, President: James C. Feliciano, "AbbVie"), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, "EA Pharma"), announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today.
Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma has been delegated by Eisai to undertake co-promotion on gastrointestinal disease indications for HUMIRA with Abbvie.
Furthermore, there will be no change to the distribution and sales framework for HUMIRA (AbbVie is the marketing and manufacturing authorization holder for HUMIRA, while Eisai is responsible for distribution).
In addition, AbbVie and Eisai will continue co-promotion for HUMIRA of indications outside of the gastrointestinal disease field (treatment of rheumatoid arthritis [including prevention of structural joint damage] and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis).
AbbVie, Eisai and EA Pharma will continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.
1. About HUMIRA
HUMIRA is a fully human anti-TNF-alpha monoclonal antibody which is approved for the following indications in Japan: "treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris; arthropathic psoriasis; ankylosing spondylitis; polyarticular juvenile idiopathic arthritis; intestinal Behcet's disease; moderate to severe active Crohn's disease as remission induction and maintenance therapy; and moderate to severe ulcerative colitis."
2. About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
AbbVie GK was established in Japan in 2013. The company employs 900 people, dedicated to developing and delivering treatments in our therapeutic areas focused on immunology, neonatology, liver disease and neuroscience, where we believe we can make a remarkable impact on the lives of patients. For further information, please visit www.abbvie.co.jp.
3. About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.
We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our "human health care (hhc)" philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
4. About EA Pharma
Established in April 2016 through the integration of Eisai's gastrointestinal disease business and AJINOMOTO PHARMACEUTICALS Co., Ltd., EA Pharma is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing.
For further information on EA Pharma Co., Ltd., please visit www.eapharma.co.jp.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Oct 30, 2025 13:43 HKT/SGT |
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Oct 28, 2025 23:30 HKT/SGT |
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| Oct 27, 2025 13:23 HKT/SGT |
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| Oct 14, 2025 16:54 HKT/SGT |
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Oct 8, 2025 11:03 HKT/SGT |
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Oct 3, 2025 17:01 HKT/SGT |
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Sept 29, 2025 09:33 HKT/SGT |
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Sept 24, 2025 18:04 HKT/SGT |
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Sept 17, 2025 17:20 HKT/SGT |
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Sept 12, 2025 12:20 HKT/SGT |
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| More news >> |
 |
|
|
|
